English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
日本語
© Reuters. FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – GSK on Wednesday said it had reached a confidential settlement on a litigation in California over claims that the British drugmaker’s heartburn drug Zantac caused cancer.
The trial for the Cantlay/Harper case, which was set to begin on November 13, will now be dismissed, GSK said.
Read the full article here
